http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 01:27:41 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html <p>Oncoinvent, a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced that its Phase 2 trial of Radspherin® has reached 50% patient enrollment, with 54 of a planned 108 patients recruited as of June 18, 2026.</p> <p>Recruitment has accelerated in 2026, with 11 patients enrolled in the first quarter and 17 in the second quarter to date. Year-to-date enrollment of 28 patients has surpassed total enrollment recorded in 2025.</p> <p>The trial (NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html Thu, 18 Jun 2026 01:27:41 -0400 A.21849991 O.08557845 O.20331252 ONCIN http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html <p>Oncoinvent, a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced that its Phase 2 trial of Radspherin® has reached 50% patient enrollment, with 54 of a planned 108 patients recruited as of June 18, 2026.</p> <p>Recruitment has accelerated in 2026, with 11 patients enrolled in the first quarter and 17 in the second quarter to date. Year-to-date enrollment of 28 patients has surpassed total enrollment recorded in 2025.</p> <p>The trial (NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html Thu, 18 Jun 2026 01:27:41 -0400 A.21849991 O.08557845 O.20331252 ONCIN http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html <p>Oncoinvent, a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced that its Phase 2 trial of Radspherin® has reached 50% patient enrollment, with 54 of a planned 108 patients recruited as of June 18, 2026.</p> <p>Recruitment has accelerated in 2026, with 11 patients enrolled in the first quarter and 17 in the second quarter to date. Year-to-date enrollment of 28 patients has surpassed total enrollment recorded in 2025.</p> <p>The trial (NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html Thu, 18 Jun 2026 01:27:41 -0400 A.21849991 O.08557845 O.20331252 ONCIN http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html <p>Oncoinvent, a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced that its Phase 2 trial of Radspherin® has reached 50% patient enrollment, with 54 of a planned 108 patients recruited as of June 18, 2026.</p> <p>Recruitment has accelerated in 2026, with 11 patients enrolled in the first quarter and 17 in the second quarter to date. Year-to-date enrollment of 28 patients has surpassed total enrollment recorded in 2025.</p> <p>The trial (NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving http://www.streetinsider.com/FDA/Oncoinvent+enrolls+54+patients+in+Phase+2+ovarian+cancer+trial/26661788.html Thu, 18 Jun 2026 01:27:41 -0400 A.21849991 O.08557845 O.20331252 ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/Press+Releases/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html <div class="xn-content"> <ul type="disc"><li><b>Strong recruitment momentum demonstrated in 2026 </b></li><li><b>Year-to-date recruitment has already surpassed total enrollment for 2025</b></li></ul><p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin^® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.</p> <p>A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has http://www.streetinsider.com/PRNewswire/Oncoinvent+achieves+50%25+recruitment+milestone+in+Phase+2+ovarian+cancer+study+of+Radspherin%C2%AE/26661787.html Thu, 18 Jun 2026 01:26:00 -0400 A.21849991 O.08557845 O.20331252 ONCIN ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/Press+Releases/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.</p> <p><b>Oncoinvent's management team will give an online presentation to investors, analysts and the press at <chron>09:30 CET</chron> today (details below).</b></p><p><b>Highlights:</b></p><p><b>Radspherin^®</b></p><ul type="disc"><li>Reported positive final data from Phase 1 Trial of Radspherin^® to treat ovarian cancer</li><li>Published Phase 1 trial results for Radspherin^® in ovarian cancer in Gynecologic Oncology</li><li>Presented final safety and efficacy results from the Phase 1/2a http://www.streetinsider.com/PRNewswire/Oncoinvent+ASA%3A+Second+half+2025+results/26062640.html Thu, 26 Feb 2026 01:26:00 -0400 O.08557845 ONCIN ONCIN OSAKA http://www.streetinsider.com/FDA/Oncoinvent+reports+phase+1+trial+results+for+ovarian+cancer+treatment/25431638.html <p>Oncoinvent ASA announced final 24-month follow-up results from its Phase 1 clinical trial evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.</p> <p>The trial enrolled 21 patients across sites in Norway, Belgium and Spain. Ten patients received the highest recommended intraperitoneal dose of 7 MBq Radspherin after dose escalation testing at 1, 2, 4 and 7 MBq levels.</p> <p>Among the 10 patients who received the highest dose, one patient experienced peritoneal recurrence, representing a 10% peritoneal recurrence rate. Two additional patients developed lymph node metastases outside the peritoneum, bringing the overall recurrence rate to 30%. The company stated that http://www.streetinsider.com/FDA/Oncoinvent+reports+phase+1+trial+results+for+ovarian+cancer+treatment/25431638.html Wed, 08 Oct 2025 01:40:40 -0400 ONCIN http://www.streetinsider.com/Press+Releases/Oncoinvent+Reports+Positive+Final+Data+from+Phase+1+Trial+of+Radspherin%C2%AE+to+Treat+Ovarian+Cancer/25431633.html <div class="xn-content"> <p> <i> <b>New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression</b> </i> </p> http://www.streetinsider.com/Press+Releases/Oncoinvent+Reports+Positive+Final+Data+from+Phase+1+Trial+of+Radspherin%C2%AE+to+Treat+Ovarian+Cancer/25431633.html Wed, 08 Oct 2025 01:24:00 -0400 ONCIN http://www.streetinsider.com/PRNewswire/Oncoinvent+Reports+Positive+Final+Data+from+Phase+1+Trial+of+Radspherin%C2%AE+to+Treat+Ovarian+Cancer/25431633.html <div class="xn-content"> <p> <i> <b>New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression</b> </i> </p> http://www.streetinsider.com/PRNewswire/Oncoinvent+Reports+Positive+Final+Data+from+Phase+1+Trial+of+Radspherin%C2%AE+to+Treat+Ovarian+Cancer/25431633.html Wed, 08 Oct 2025 01:24:00 -0400 ONCIN